Cardiff Oncology CSO awarded 300,000 stock options

Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share.

Rhea-AI Filing Summary

Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share. These options were awarded as compensation, not purchased in the open market, and expire on April 14, 2036.

Following this grant, Smeal holds stock options for 1,279,805 shares in total. The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly for 36 months thereafter, creating a multi‑year retention and incentive structure.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Smeal Tod

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	300,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,279,805 contracts (Direct)

Footnotes (1)

1. F1. 75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter

Key Figures

Options granted: 300,000 options Exercise price: $1.63 per share Total options after grant: 1,279,805 options +3 more

6 metrics

Options granted 300,000 options Grant to Chief Scientific Officer on April 14, 2026

Exercise price $1.63 per share Strike price for newly granted options

Total options after grant 1,279,805 options Derivative holdings following the reported transaction

Expiration date April 14, 2036 Final exercise date for the granted options

Initial vesting tranche 75,000 options Vests on April 14, 2027

Monthly vesting amount 6,250 options Vest monthly for 36 months after April 14, 2027

Key Terms

stock options, exercise price, derivative securities, vesting, +1 more

5 terms

stock options financial

"Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares of common stock as derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 regulatory

"After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares reported on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardiff Oncology (CRDF) report for Tod Smeal?

Cardiff Oncology reported that Chief Scientific Officer Tod Smeal received a grant of 300,000 stock options. The options relate to common stock and were issued as compensation under a vesting schedule, rather than being bought or sold in the open market.

What is the exercise price and expiration date of Tod Smeal’s new CRDF stock options?

Tod Smeal’s newly granted Cardiff Oncology stock options have an exercise price of $1.63 per share. The options expire on April 14, 2036, giving a long-dated window in which they may be exercised if vesting conditions are satisfied.

How do Tod Smeal’s Cardiff Oncology stock options vest over time?

The grant includes time-based vesting: 75,000 options vest on April 14, 2027. An additional 6,250 options then vest monthly for 36 months, creating a staggered schedule that extends vesting over several years to support ongoing retention.

How many Cardiff Oncology derivative securities does Tod Smeal hold after this Form 4?

After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares of Cardiff Oncology common stock. This figure reflects his total derivative holdings reported in the filing following the award of the 300,000 new options.

Does Tod Smeal’s Form 4 for CRDF indicate any open-market buying or selling of shares?

The Form 4 shows a grant of stock options classified as a derivative acquisition, not an open-market trade. The transaction code is “A,” meaning a grant or award, and no purchase or sale of common shares is reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smeal Tod

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.63	04/14/2026		A		300,000		(1)	04/14/2036	Common Stock	300,000	$0	1,279,805	D

Explanation of Responses:

1. 75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter

	/s/ Tod Smeal	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)